Oreola Donini - Soligenix Insider

SNGX -- USA Stock  

USD 1.22  0.07  6.09%

Dr. Oreola Donini, Ph.D., is Senior Vice President, Chief Scientific Officer of Soligenix, Inc. Dr. Donini served as our Vice President of Preclinical Research and Development from August 15, 2013 until December 4, 2014. She has more than 15 years experience in drug discovery and preclinical development with startup biotechnology companies. From 2012 to 2013, Dr. Donini worked with ESSA Pharma Inc. as Vice President Research and Development. From 2004 to 2012, Dr. Donini worked with Inimex Pharmaceuticals Inc.,, lastly as Senior Director of Preclinical RD from 20072013. Prior to joining Inimex, she worked with Kinetek Pharmaceuticals Inc., developing therapies for infectious disease, cancer and cancer supportive care. Dr. Donini is a coinventor and leader of the Companys SGX94 innate defense regulator technology, developed by Inimex and subsequently acquired by the Company. She was responsible for overseeing the manufacturing and preclinical testing of SGX94, which demonstrated efficacy in combating bacterial infections and mitigating the effects of tissue damage due to trauma, infection, radiation andor chemotherapy treatment. These preclinical studies resulted in a successful Phase 1 clinical study and clearance of Phase 2 protocols for oral mucositis in head and neck cancer and acute bacterial skin and skin structure infections. While with ESSA Pharma Inc. as the Vice President of Research and Development, Dr. Donini led the preclinical testing of a novel Nterminal domain inhibitor of the androgen receptor for the treatment of prostate cancer. While with Kinetek Pharmaceuticals Inc., her work related to the discovery of novel kinase and phosphatase inhibitors for the treatment of cancer
Age: 42  SVP Since 2014  Ph.D    
609-538-8200  http://www.soligenix.com
Donini received her PhD from Queen?s University in Kinston, Ontario, Canada and completed her postdoctoral work at the University of California.

Oreola Donini Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (64.9) % which means that it has lost $64.9 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (157.6) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey. Soligenix operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 18 people.Soligenix (SNGX) is traded on Nasdaq Capital Markets in USA. It is located in 29 Emmons Drive and employs 18 people.

Soligenix Leadership Team

Jerome Zeldis, Independent Director
Richard Straube, Senior Vice President and Chief Medical Officer
Marco Brughera, Director
Oreola Donini, Chief Scientific Officer and Sr. VP
Gregg Lapointe, Independent Director
Keith Brownlie, Independent Director
Christopher Schaber, Chairman, CEO and Pres
Karen Krumeich, CFO, Senior Vice President
Joseph Warusz, Acting CFO, Vice President - Finance, Corporate Secretary
Robert Rubin, Independent Director
Anthony Lapointe, Independent Director

Stock Performance Indicators

Did you try this?

Run Performance Analysis Now

Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
All  Next Launch Performance Analysis
Currently Active Assets on Macroaxis
Purchased over 20 shares of
2 days ago
Traded for 106.27
Purchased over 200 shares of
2 days ago
Traded for 10.56
Purchased over 70 shares of
2 days ago
Traded for 39.4
Purchased few shares of
2 days ago
Traded for 1184.91
Purchased over 40 shares of
2 days ago
Traded for 69.22
Also please take a look at World Market Map. Please also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.